TY - JOUR AU - E Domingo-Domenech, AU - E Gonzalez-Barca, AU - C Estany, AU - A Sureda, AU - J Besalduch, AU - A Fernandez de Sevilla, PY - 2002/11/01 Y2 - 2024/03/29 TI - Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas JF - Haematologica JA - haematol VL - 87 IS - 11 SE - Clinical Trial DO - 10.3324/%x UR - https://haematologica.org/article/view/2560 SP - 1229-1230 AB - We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 months, 63% of the patients are alive (50% CR). The combination of rituximab and CHOP in relapsed advanced-stage follicular lymphomas achieves high ORRs and CRs, with low toxicity except for in previously autografted patients. ER -